A targetable type III immune response with increase of IL-17A expressing CD4+ T cells is associated with immunotherapy-induced toxicity in melanoma.
Dimitriou F, Cheng PF, Saltari A, Schaper-Gerhardt K, Staeger R, Haunerdinger V, Sella F, Tastanova A, Urban C, Dettwiler S, Mihic-Probst D, Matter CM, Michielin O, Gutzmer R, Long GV, Becher B, Levesque MP, Dummer R.
Dimitriou F, et al. Among authors: dettwiler s.
Nat Cancer. 2024 Sep;5(9):1390-1408. doi: 10.1038/s43018-024-00810-4. Epub 2024 Aug 29.
Nat Cancer. 2024.
PMID: 39210005
Free PMC article.